Gene-Based Therapies for Dominant Retinopathies

Current Gene Therapy

Volumn 10, Issue 5, 2010, Pages 381-388

  Farrar, G Jane ^a   Palfi, Arpad ^a   Kenna, Paul F ^a   O'Reilly, Mary ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Dominant retinopathies; Gene therapy; Retina; RNA interference

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR; ROD DERIVED CONE VIABILITY FACTOR PROTEIN; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; AUTOSOMAL DOMINANT DISORDER; CLINICAL TRIAL (TOPIC); GENE REPRESSION; GENE TARGETING; GENE THERAPY; GENETIC HETEROGENEITY; HUMAN; RETINITIS PIGMENTOSA; RETINOPATHY; REVIEW; DOMINANT GENE; GENE TRANSFER; GENETICS; RETINA DEGENERATION; RETINA DISEASE;

ANIMALIA;

GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, DOMINANT; HUMANS; RETINAL DEGENERATION; RETINAL DISEASES;

EID: 78651312593     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652310793180661     Document Type: Review

References (108)

1. Goldberg AF, Molday RS. Defective subunit assembly underlies adigenic form of retinitis pigmentosa linked to mutations in peripherin/rds and rom-1. Proc Natl Acad Sci U S A 1996; 93: 13726-30.
2. Mansergh FC, Millington-Ward S, Kennan A, et al. Retinitis pigmentosaand progressive sensorineural hearing loss caused by aC 12258A mutation in the mitochondrial MTTS2 gene. Am J Hum Genet 1999; 64: 971-85.
3. Ayuso C, Millan JM. Retinitis pigmentosa and allied conditionstoday: a paradigm of translational research. Genome Med 2010; 2: 34.
4. McWilliam P, Farrar GJ, Kenna P, et al. Autosomal dominantretinitis pigmentosa (ADRP): localization of an ADRP gene to thelong arm of chromosome 3. Genomics 1989; 5: 619-22.
5. Dryja TP, McGee TL, Reichel E, et al. A point mutation of therhodopsin gene in one form of retinitis pigmentosa. Nature 1990; 343: 364-6.
6. Dryja TP, McGee TL, Hahn LB, et al. Mutations within therhodopsin gene in patients with autosomal dominant retinitis pigmentosa. N Engl J Med 1990; 323: 1302-7.
7. Inglehearn CF, Tarttelin EE, Plant C, et al. A linkage survey of 20dominant retinitis pigmentosa families: frequencies of the nineknown loci and evidence for further heterogeneity. J Med Genet 1998; 35: 1-5.
8. Sohocki MM, Daiger SP, Bowne SJ, et al. Prevalence of mutationscausing retinitis pigmentosa and other inherited retinopathies. Hum Mutat 2001; 17: 42-51
9. Sullivan LS, Bowne SJ, Birch DG, et al. Prevalence of diseasecausingmutations in families with autosomal dominant retinitispigmentosa: a screen of known genes in 200 families. Invest Ophthalmol Vis Sci 2006; 47: 3052-64.
10. Allocca M, Tessitore A, Cotugno G, et al. AAV-mediated genetransfer for retinal diseases. Expert Opin Biol Ther 2006; 6: 1279-94.
11. Pang JJ, Boye SL, Kumar A, et al. AAV-mediated gene therapy forretinal degeneration in the rd10 mouse containing a recessive PDEbetamutation. Invest Ophthalmol Vis Sci 2008; 49: 4278-83.
12. Tan MH, Smith AJ, Pawlyk B, et al. Gene therapy for retinitispigmentosa and Leber congenital amaurosis caused by defects inAIPL1: effective rescue of mouse models of partial and completeAipl1 deficiency using AAV2/2 and AAV2/8 vectors. Hum Mol Genet 2009; 18: 2099-114.
13. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores visionin a canine model of childhood blindness. Nat Gen 2001; 28: 92-95.
14. Le Meur G, Stieger K, Smith AJ, et al. Restoration of vision inRPE65-deficient Briard dogs using an AAV serotype 4 vector thatspecifically targets the retinal pigmented epithelium. Gene Ther 2007; 14: 292-303.
15. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapyon visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358: 2231-9.
16. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy ofgene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-8.
17. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapyfor RPE65 isomerase deficiency activates the retinoid cycle of visionbut with slow rod kinetics. Proc Natl Acad Sci U S A 2008; 105: 15112-7.
18. Maguire M, High KA, Auricchio A, et al. Age-dependent effects ofRPE65 gene therapy for Leber's congenital amaurosis: a phase 1dose-escalation trial. Lancet 2009; 374: 1597-605 Erratum in: Lancet 2010; 375: 30.
19. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber'scongenital amaurosis is safe and effective through 1.5 years aftervector administration. Mol Ther 2010; 18: 643-50.
20. Emerich DF, Thanos CG. NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells. Curr Opin Mol Ther 2008; 10: 506-15.
21. Gregory-Evans K, Chang F, Hodges MD, et al. Ex vivo gene therapyusing intravitreal injection of GDNF-secreting mouse embryonicstem cells in a rat model of retinal degeneration. Mol Vis 2009; 15: 962-73.
22. Rex TS, Wong Y, Kodali K, et al. Neuroprotection of photoreceptorsby direct delivery of erythropoietin to the retina of the retinaldegeneration slow mouse. Exp Eye Res 2009; 89: 735-40.
23. Yang Y, Mohand-Said S, Danan A, et al. Functional cone rescueby Rd CVF protein in a dominant model of retinitis pigmentosa. Mol Ther 2009; 17: 787-95.
24. Samardzija M, Wenzel A, Thiersch M, et al. Caspase-1 ablationprotects photoreceptors in a model of autosomal dominant retinitispigmentosa. Invest Ophthalmol Vis Sci 2006; 47: 5181-90.
25. Osakada F, Ikeda H, Sasai Y, et al. Stepwise differentiation ofpluripotent stem cells into retinal cells. Nat Protoc 2009; 4: 811-24.
26. Lamba DA, McUsic A, Hirata RK, et al. Generation, purificationand transplantation of photoreceptors derived from human inducedpluripotent stem cells. PLo S One 2010; 5: e8763.
27. Komeima K, Rogers BS, Campochiaro PA. Antioxidants slowphotoreceptor cell death in mouse models of retinitis pigmentosa. JCell Physiol 2007; 213: 809-15.
28. Usui S, Komeima K, Lee SY, et al. Increased expression of catalaseand superoxide dismutase 2 reduces cone cell death in retinitispigmentosa. Mol Ther 2009; 17: 778-86.
29. Gorbatyuk MS, Knox T, La Vail MM, et al. Restoration of visualfunction in P23H rhodopsin transgenic rats by gene delivery ofBi P/Grp78. Proc Natl Acad Sci U S A 2010; 107: 5961-6.
30. Lin JH, Lavail MM. Misfolded proteins and retinal dystrophies. Adv Exp Med Biol 2010; 664: 115-21.
31. Bull ND, Martin KR. Using stem cells to mend the retina in oculardisease. Regen Med 2009; 4: 855-64. Review.
32. Bi YY, Feng DF, Pan DC. Stem/progenitor cells: a potential sourceof retina-specific cells for retinal repair. Neurosci Res 2009; 65: 215-21. Review.
33. Lamba DA, Karl MO, Reh TA. Strategies for retinal repair: cellreplacement and regeneration. Prog Brain Res 2009; 175: 23-31. Review.
34. Comyn O, Lee E, Mac Laren RE. Induced pluripotent stem celltherapies for retinal disease. Curr Opin Neurol 2010; 23: 4-9. Review.
35. Belikova AM, Zarytova VF, Grineva NI. Synthesis of ribonucleosidesand diribonucleoside phosphates containing 2-chloroethylamine and nitrogen mustard residues. Tetrahedron Lett 1967; 37: 3557-62.
36. Takayama KM, Inouye M. Antisense RNA. Crit Rev Biochem Mol Biol 1990; 25: 155-84. Review.
37. Colman A. Antisense strategies in cell and developmental biology. J Cell Sci 1990; 97: 399-409.
38. Cohen J. Oligonucleotide antisense inhibitors of gene expression.1989; CRC Press, Boca Taton, FL.
39. Bass BL, Cech TR. Specific interaction between the self-splicingRNA of Tetrahymena and its guanosine substrate: implications forbiological catalysis by RNA. Nature 1984; 308: 820-6.
40. Guerrier-Takada C, Altman S. Catalytic activity of an RNA moleculeprepared by transcription in vitro. Science 1984; 223: 285-6.
41. Fire A, Xu S, Montgomery MK, et al. Potent and specific geneticinterference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-11.
42. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimericchalcone synthase gene into petunia results in reversible cosuppressionof homologous genes in trans. Plant Cell 1990; 2: 279-89.
43. Bridge AJ, Pebernard S, Ducraux A, et al. Induction of an interferonresponse by RNAi vectors in mammalian cells. Nat Genet 2003; 34: 263-4.
44. Moss EG, Taylor JM. Small-interfering RNAs in the radar of theinterferon system. Nat Cell Biol 2003; 5: 771-2.
45. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cellculture. Nature 2001; 411: 494-498.
46. Heidel JD, Hu S, Liu XF, et al. Lack of interferon response inanimals to naked siRNAs. Nature Biotechnol 2004; 22: 1579-82.
47. Scherr M, Morgan MA, Eder M. Gene silencing mediated by smallinterfering RNAs in mammalian cells. Curr Med Chem 2003; 10: 245-56
48. Jaskiewicz L, Filipowicz W. Role of Dicer in posttranscriptionalRNA silencing. Curr Top Microbiol Immunol 2008; 320: 77-97.
49. Manjunath N, Dykxhoorn DM. Advances in synthetic siRNA delivery. Discov Med 2010; 9: 418-30.
50. Qureshi IA, Mehler MF. Regulation of non-coding RNA networksin the nervous system-what's the REST of the story? Neurosci Lett 2009; 466: 73-80.
51. Freund A, Orjalo AV, Desprez PY, et al. Inflammatory networksduring cellular senescence: causes and consequences. Trends Mol Med 2010; 16: 238-46.
52. Loscher CJ, Hokamp K, Kenna PF, et al. Altered retinal microRNAexpression profile in mouse model of retinitis pigmentosa. Genome Biol 2007; 8: R248
53. Loscher CJ, Hokamp K, Wilson JH, et al. A common microRNAsignature in mouse models of retinal degeneration. Exp Eye Res 2008; 87: 529-34.
54. Xu S. Micro RNA expression in the eyes and their significance inrelation to functions. Prog Retin Eye Res 2009; 28: 87-116. Review.
55. Tan S, Guschin D, Davalos A, et al. Zinc-finger protein-targetedgene regulation: genomewide single-gene specificity. Proc Natl Acad Sci USA 2003; 100: 11997-200256.
56. Tuerk C, Gold L. Systematic evolution of ligands by exponentialenrichment: RNA ligands to bacterial T4 DNA polymerase. Science 1990; 249: 505-10.
57. Akiyama H, Kachi S, Silva RL, et al. Intraocular injection of anaptamer that binds PDGF-B: a potential treatment for proliferativeretinopathies. J Cell Physiol 2006; 207: 407-12.
58. Trujillo CA, Nery AA, Alves JM, et al. Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology. Clin Ophthalmol 2007; 1: 393-402.
59. Baehr W, Frederick JM. Naturally occurring animal models withouter retina phenotypes. Vision Res 2009; 49: 2636-52.
60. Rivas, MA, Vecino E. Animal models and different therapies fortreatment of retinitis pigmentosa. Histol Histopathol 2009; 24: 1295-322
61. Olsson JE, Gordon JW, Pawlyk BS, et al. Transgenic mice with arhodopsin mutation (Pro23His): a mouse model of autosomaldominant retinitis pigmentosa. Neuron 1992; 9: 815-30.
62. Li T, Snyder WK, Olsson JE et al. Transgenic mice carrying thedominant rhodopsin mutation P347S: Evidence for defective vectorialtransport of rhodopsin to the outer segments. Proc Natl Acad Sci USA 1996; 93: 14176-81.
63. Li T, Sandberg MA, Pawlyk BS, et al. Effect of vitamin A supplementationon rhodopsin mutants threonine-17--> methionine andproline-347--> serine in transgenic mice and in cell cultures. Proc Natl Acad Sci U S A 1998; 95: 11933-8.
64. Naash MI, Hollyfield JG, al-Ubaidi MR, et al. Simulation of humanautosomal dominant retinitis pigmentosa in transgenic miceexpressing a mutated murine opsin gene. Proc Natl Acad Sci USA 1993; 90: 5499-503.
65. Li T, Franson WK, Gordon JW, et al. Constitutive activation ofphototransduction by K296E opsin is not a cause of photoreceptordegeneration. Proc Natl Acad Sci U S A 1995; 92: 3551-5.
66. Portera-Cailliau C, Sung CH, Nathans J, et al. Apoptotic photoreceptorcell death in mouse models of retinitis pigmentosa. Proc Natl Acad Sci U S A 1994; 91: 974-8.
67. Steinberg RH, Flannery JG, Naash M, et al. Transgenic rat modelsof inherited retinal degeneration caused by mutant opsin genes. Invest Ophthalmol Vis Sci 1996; 37 S698.
68. Petters RM, Alexander CA, Wells KD, et al. Genetically engineeredlarge animal model for studying cone photoreceptor survivaland degeneration in retinitis pigmentosa. Nat Biotechnol 1997; 15: 965-70.
69. Zhu L, Jang GF, Jastrzebska B, et al. A naturally occurring mutationof the opsin gene (T4R) in dogs affects glycosylation and stabilityof the G protein-coupled receptor. J Biol Chem 2004; 279: 53828-39.
70. Kijas JW, Miller BJ, Pearce-Kelling SE, et al. Canine models ofocular disease: outcross breedings define a dominant disorder presentin the English mastiff and bull mastiff dog breeds. J Hered 2003; 94: 27-30.
71. Sakai T, Kondo M, Ueno S, et al. Supernormal ERG oscillatorypotentials in transgenic rabbit with rhodopsin P347L mutation andretinal degeneration. Invest Ophthalmol Vis Sci 2009; 50: 4402-9.
72. Kedzierski W, Lloyd M, Birch DG, et al. Generation and analysisof transgenic mice expressing P216L-substituted rds/peripherin inrod photoreceptors. Invest Ophthalmol Vis Sci 1997; 38: 498-509.
73. McNally N, Kenna PF, Rancourt D, et al. Murine model of autosomaldominant retinitis pigmentosa generated by targeted deletionat codon 307 of the rds-peripherin gene. Hum Mol Genet 2002; 11: 1005-16
74. Raz-Prag D, Ayyagari R, Fariss RN, et al. Haploinsufficiency isnot the key mechanism of pathogenesis in a heterozygous Elovl4knockout mouse model of STGD3 disease. Invest Ophthalmol Vis Sci 2006; 47: 3603-11.
75. McMahon A, Butovich IA, Mata NL, et al. Retinal pathology andskin barrier defect in mice carrying a Stargardt disease-3 mutationin elongase of very long chain fatty acids-4. Mol Vis 2007; 13: 258-72.
76. Vasireddy V, Wong P, Ayyagari R. Genetics and molecular pathologyof Stargardt-like macular degeneration. Prog Retin Eye Res 2010; 29: 191-207
77. Tam LC, Kiang AS, Kennan A, et al. Therapeutic benefit derivedfrom RNAi-mediated ablation of IMPDH1 transcripts in a murinemodel of autosomal dominant retinitis pigmentosa (RP10) Hum Mol Genet 2008; 17: 2084-100.
78. Qi X, Sun L, Lewin AS, et al. The mutant human ND4 subunit ofcomplex I induces optic neuropathy in the mouse. Invest Ophthalmol Vis Sci 2007; 48: 1-10.
79. Millington-Ward S, McMahon HP, Allen D, et al. RNAi ofCOL1A1 in mesenchymal progenitor cells. Eur J Hum Genet 2004; 12: 864-6.
80. La Vail MM, Yasumura D, Matthes MT, et al. Ribozyme rescue ofphotoreceptor cells in P23H transgenic rats: long-term survival andlate-stage therapy. Proc Natl Acad Sci USA 2000; 97: 11488-93.
81. Tessitore A, Parisi F, Denti MA, et al. Preferential silencing of acommon dominant rhodopsin mutation does not inhibit retinal degenerationin a transgenic model. Mol Ther 2006; 14: 692-9.
82. Millington-Ward S, O'Neill B, Tuohy G, et al. Strategems in vitrofor gene therapies directed to dominant mutations. Hum Mol Genet 1997; 6: 1415-26.
83. Hauswirth WW, Lewin AS. Ribozyme uses in retinal gene therapy. Prog Retin Eye Res 2000; 19: 689-710
84. Kiang AS, Palfi A, Ader M, et al. Toward a gene therapy for dominantdisease: validation of an RNA interference-based mutationindependentapproach. Mol Ther 2005; 12: 555-61.
85. Cashman SM, Binkley EA, Kumar-Singh R. Towards mutationindependent silencing of genes involved in retinal degeneration byRNA interference. Gene Ther 2005; 12: 1223-8
86. Palfi A, Ader M, Kiang AS, et al. RNAi-based suppression andreplacement of RDS-peripherin in retinal organotypic culture. Hum Mutat 2006; 27: 260-8.
87. O'Reilly M, Palfi A, Chadderton N, et al. RNA interferencemediatedsuppression and replacement of human rhodopsin in vivo. Am J Hum Genet 2007; 81: 127-35.
88. Chadderton N, Millington-Ward S, Palfi A, et al. Improved retinalfunction in a mouse model of dominant retinitis pigmentosa followingAAV-delivered gene therapy. Mol Ther 2009; 17: 593-9.
89. Palfi A, Millington-Ward S, Chadderton N, et al. Adeno-associatedvirus-mediated rhodopsin replacement provides therapeutic benefitin mice with a targeted disruption of the rhodopsin gene. Hum Gene Ther 2010; 21: 311-23.
90. Durai S, Mani M, Kandavelou K, et al. Zinc finger nucleases:custom-designed molecular scissors for genome engineering ofplant and mammalian cells. Nucleic Acids Res 2005; 33: 5978-90.
91. Gu JJ, Tolin AK, Jain J, et al. Targeted disruption of the inosine 5'-monophosphate dehydrogenase type I gene in mice. Mol Cell Biol 2003; 23: 6702-12.
92. Humphries MM, Rancourt D, Farrar GJ, et al. Retinopathy inducedin mice by targeted disruption of the rhodopsin gene. Nat Genet 1997; 15: 216-9.
93. Lem J, Krasnoperova NV, Calvert PD, et al. Morphological, physiological, and biochemical changes in rhodopsin knockoutmice. Proc Natl Acad Sci USA 1999; 96: 736-41.
94. Kang MJ, Ryoo HD. Suppression of retinal degeneration in Drosophilaby stimulation of ER-associated degradation. Proc Natl Acad Sci U S A 2009; 106: 17043-8.
95. Kosmaoglou M, Kanuga N, Aguilà M, et al. A dual role forEDEM1 in the processing of rod opsin. J Cell Sci 2009; 122: 4465-72.
96. Bainbridge JW, Tan MH, Ali RR. Gene therapy progress and prospects:the eye. Gene Ther 2006; 13: 1191-7. Review.
97. Bennett J, Tanabe T, Sun D, et al. Photoreceptor cell rescue inretinal degeneration (rd) mice by in vivo gene therapy. Nat Med 1996; 2: 649-54.
98. Loewen N, Leske DA, Cameron JD, et al. Long-term retinal transgeneexpression with FIV versus adenoviral vectors. Mol Vis 2004; 10: 272-80.
99. Kong J, Kim SR, Binley K, et al. Correction of the disease phenotypein the mouse model of Stargardt disease by lentiviral genetherapy. Gene Ther 2008; 15: 1311-20.
100. Bemelmans AP, Kostic C, Crippa SV, et al. Lentiviral gene transferof RPE65 rescues survival and function of cones in a mouse modelof Leber congenital amaurosis. PLo S Med 2006; 3: e347.
101. Auricchio A. Pseudotyped AAV vectors for constitutive and regulatedgene expression in the eye. Vision Res 2003; 43: 913-8. Review.
102. Allocca M, Doria M, Petrillo M, et al. Serotype-dependent packagingof large genes in adeno-associated viral vectors results in effectivegene delivery in mice. J Clin Invest 2008; 118: 1955-64.
103. Dong B, Nakai H, Xiao W. Characterization of genome integrityfor oversized recombinant AAV vector. Mol Ther 2010; 18: 87-92.
104. Lai Y, Yue Y, Duan D. Evidence for the failure of adenoassociatedvirus serotype 5 to package a viral genome > or = 8.2kb. Mol Ther 2010; 18: 75-9.
105. Cai X, Conley SM, Naash Z, et al. Gene delivery to mitotic andpostmitotic photoreceptors via compacted DNA nanoparticles resultsin improved phenotype in a mouse model of retinitis pigmentosa. FASEB J 2010; 24: 1178-91
106. Hangai M, Kaneda Y, Tanihara H, et al. In vivo gene transfer intothe retina mediated by a novel liposome system. Invest Ophthalmol Vis Sci 1996; 37: 2678-85.
107. Matsuda T, Cepko CL. Electroporation and RNA interference inthe rodent retina in vivo and in vitro. Proc Natl Acad Sci U S A 2004; 101: 16-22.
108. Terzi D, Zachariou V. Adeno-associated virus-mediated gene deliveryapproaches for the treatment of CNS disorders. Biotechnol J 2008; 3: 1555-63.